Synaptrix scores $10m for postoperative pain relief device
Synaptrix, an Atlanta based medical device startup, announces Series A First-Close of $10M to develop NOVABLOC™, a first-in-kind drug-free solution for extended post-surgical pain relief and elimination of opioids. Proceeds will support a pivotal study, regulatory submission, and commercialization of the company’s proprietary NOVABLOC™ system.
The team announced a $10 million Series A last week from lead investor Hatteras Venture Partners. Rex Health Ventures, the corporate venture arm of UNC Health, Alpharetta-based Avanos Medical, and Portal Innovations also participated in the round.
“Modern day treatments for postoperative pain management are largely insufficient. They are either plagued by short-lasting pain control, limit physical rehabilitation, or invite opioid use,” said Founder and CEO Shyamy Sastry. “The NOVABLOC™ system is a groundbreaking neuromodulation technology designed to deliver 20+ days of pain relief without impacting motor function or touch. Altogether, the system treats postoperative pain for days to weeks while promoting rehabilitation and reducing the need for opioids.”
The NOVABLOC™ system will initially be studied as a procedure-based treatment for postoperative pain arising from total knee arthroplasty (TKA) procedures, and other indications will follow. Synaptrix has performed multiple human feasibility studies investigating the NOVABLOC™ treatment. A sham-controlled feasibility study conducted in 32 persons undergoing a primary TKA procedure showed that the NOVABLOC™ treatment delivered to mixed peripheral nerves prior to surgery enabled 20 days of pain relief and preserved motor function, the sense of touch, and proprioception in the treated limb. Moreover, subjects in the treatment group demonstrated better functional outcomes, less opioid use, and less healthcare utilization.
Lead investor Doug Reed, MD from Hatteras Venture Partners, said, “We are impressed with the clinical data developed so far and believe that this technique could represent a major benefit to patients undergoing this often painful TKA surgery and the subsequent difficult physical therapy rehabilitation.”
about Synaptrix: Synaptrix is a medical device company dedicated to developing and commercializing drug-free pain management solutions for postoperative joint surgery patients. Starting as a spin-out in 2023, the proprietary NOVABLOC™ system is a procedure-based solution that delivers a novel type of electrical stimulation. Human feasibility studies have demonstrated 20+ days of pain relief with a single treatment, sparing motor function, touch, and proprioception. Synaptrix is committed to reducing opioids and prioritizes patient well-being by developing an innovative, user-friendly solution that addresses an unmet medical need.